Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

ALTHEA Gold Libraries™: antibody libraries for therapeutic antibody discovery.

Valadon P, Pérez-Tapia SM, Nelson RS, Guzmán-Bringas OU, Arrieta-Oliva HI, Gómez-Castellano KM, Pohl MA, Almagro JC.

MAbs. 2019 Apr;11(3):516-531. doi: 10.1080/19420862.2019.1571879. Epub 2019 Feb 26.

2.

A universal phage display system for the seamless construction of Fab libraries.

Nelson RS, Valadon P.

J Immunol Methods. 2017 Nov;450:41-49. doi: 10.1016/j.jim.2017.07.011. Epub 2017 Jul 26.

PMID:
28756139
3.

Construction of metabolically biotinylated adenovirus with deleted fiber knob as targeting vector.

Liu Y, Valadon P, Schnitzer JE.

Virol J. 2010 Nov 12;7:316. doi: 10.1186/1743-422X-7-316.

4.

Lung vascular targeting using antibody to aminopeptidase P: CT-SPECT imaging, biodistribution and pharmacokinetic analysis.

Chrastina A, Valadon P, Massey KA, Schnitzer JE.

J Vasc Res. 2010;47(6):531-43. doi: 10.1159/000313880. Epub 2010 Apr 30.

5.

Designed auto-assembly of nanostreptabodies for rapid tissue-specific targeting in vivo.

Valadon P, Darsow B, Buss TN, Czarny M, Griffin NM, Nguyen HN, Oh P, Borgstrom P, Chrastina A, Schnitzer JE.

J Biol Chem. 2010 Jan 1;285(1):713-22. doi: 10.1074/jbc.M109.061838. Epub 2009 Oct 22.

6.

Screening phage display libraries for organ-specific vascular immunotargeting in vivo.

Valadon P, Garnett JD, Testa JE, Bauerle M, Oh P, Schnitzer JE.

Proc Natl Acad Sci U S A. 2006 Jan 10;103(2):407-12. Epub 2005 Dec 29.

7.
8.
10.

Melanization of Cryptococcus neoformans in murine infection.

Nosanchuk JD, Valadon P, Feldmesser M, Casadevall A.

Mol Cell Biol. 1999 Jan;19(1):745-50.

11.
12.

Characterization of a murine monoclonal antibody to Cryptococcus neoformans polysaccharide that is a candidate for human therapeutic studies.

Casadevall A, Cleare W, Feldmesser M, Glatman-Freedman A, Goldman DL, Kozel TR, Lendvai N, Mukherjee J, Pirofski LA, Rivera J, Rosas AL, Scharff MD, Valadon P, Westin K, Zhong Z.

Antimicrob Agents Chemother. 1998 Jun;42(6):1437-46.

14.

Peptide inhibition of glomerular deposition of an anti-DNA antibody.

Gaynor B, Putterman C, Valadon P, Spatz L, Scharff MD, Diamond B.

Proc Natl Acad Sci U S A. 1997 Mar 4;94(5):1955-60.

15.

Epitope location in the Cryptococcus neoformans capsule is a determinant of antibody efficacy.

Nussbaum G, Cleare W, Casadevall A, Scharff MD, Valadon P.

J Exp Med. 1997 Feb 17;185(4):685-94.

16.
17.

Enhancement of ELISAs for screening peptides in epitope phage display libraries.

Valadon P, Scharff MD.

J Immunol Methods. 1996 Oct 16;197(1-2):171-9.

PMID:
8890904
18.

Peptide libraries define the fine specificity of anti-polysaccharide antibodies to Cryptococcus neoformans.

Valadon P, Nussbaum G, Boyd LF, Margulies DH, Scharff MD.

J Mol Biol. 1996 Aug 9;261(1):11-22.

PMID:
8760499
19.

Specificity of in vitro covalent binding of tienilic acid metabolites to human liver microsomes in relationship to the type of hepatotoxicity: comparison with two directly hepatotoxic drugs.

Lecoeur S, Bonierbale E, Challine D, Gautier JC, Valadon P, Dansette PM, Catinot R, Ballet F, Mansuy D, Beaune PH.

Chem Res Toxicol. 1994 May-Jun;7(3):434-42.

PMID:
8075377
20.

Immunotoxicology and expression of human cytochrome P450 in microorganisms.

Beaune P, Bourdi M, Belloc C, Gautier JC, Guengerich FP, Valadon P.

Toxicology. 1993 Oct 5;82(1-3):53-60.

PMID:
8236281
21.

Human-liver cytochromes P-450 expressed in yeast as tools for reactive-metabolite formation studies. Oxidative activation of tienilic acid by cytochromes P-450 2C9 and 2C10.

Lopez Garcia MP, Dansette PM, Valadon P, Amar C, Beaune PH, Guengerich FP, Mansuy D.

Eur J Biochem. 1993 Apr 1;213(1):223-32.

Supplemental Content

Loading ...
Support Center